Immunologiya, Год журнала: 2022, Номер 43(5), С. 558 - 570
Опубликована: Янв. 1, 2022
Особенности иммунного ответа на опухолевые штаммы EL-4 у мышей линий C57BL/6, В10.D2 (R101) и BALB/c 1 Фонд перспективных исследований, 121059, г.Москва, Российская Федерация 2 Федеральное государственное бюджетное учреждение «Государственный научный центр «Институт иммунологии» Федерального медико-
Язык: Русский
Biomedicine & Pharmacotherapy, Год журнала: 2022, Номер 156, С. 113906 - 113906
Опубликована: Окт. 25, 2022
Tumor microenvironment (TME) takes critical roles in tumor resistance to immune checkpoint inhibitors (ICIs) including anti-programmed death-1 (PD-1) or death-ligand 1 (PD-L1). Cancer stem cells (CSCs) are one of the key components TME that play important immunoregulation and therapy resistance. CSCs suppress CD8+ T cell infiltration, promote recruitment type 2 macrophages (M2) activity neutrophils (N2). There is a positive association between CSC expansion with high PD-L1 expression TME, higher than cancer cells. metastatic induces dedifferentiation program through stimulating an epithelial-mesenchymal transition (EMT) profile, thereby replenishing proportion inside tumor. Conversion from EMT mesenchymal-epithelial (MET) downregulates on non-CSCs increases ICI efficacy. evidence replenishment secondary anti-PD-1 therapy. Targeting is, fact, step effective breakdown reducing recurrence after immunotherapy. A number signaling involved enrichment within area, among them focus over transforming growth factor-β (TGF-β). TGF-β program, its as bridge increased level rationalizes application dual TGF-β/anti-PD-L1 strategy for reinvigorating immunoactivities patients under In this review, we aimed discuss about connections ecosystem impact such interactions responses
Язык: Английский
Процитировано
49
Life Sciences, Год журнала: 2023, Номер 318, С. 121459 - 121459
Опубликована: Янв. 30, 2023
Язык: Английский
Процитировано
28
Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 163, С. 114890 - 114890
Опубликована: Май 15, 2023
B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of family that aberrantly and consistently expressed in several human cancers, its overexpression correlates with weak prognosis. B7-H3 on number cells, it acts as driver immune evasion. This mediated through hampering T cell infiltration promoting exhaustion CD8+ cells. Increased activity promotes macrophage polarity toward pro-tumor type 2 (M2) phenotype. In addition, high induces aberrant angiogenesis to promote hypoxia, result which resistance common inhibitor (ICI) therapy. the impact hypoxia dampening recruitment into tumor area. The immunosuppressive property offers insights targeting this desired approach cancer immunotherapy. can be target blocking monoclonal antibodies (mAbs), combination therapies, chimeric antigen receptor-modified (CAR-T) cells bispecific antibodies.
Язык: Английский
Процитировано
26
Pathology - Research and Practice, Год журнала: 2025, Номер 270, С. 155992 - 155992
Опубликована: Апрель 28, 2025
Язык: Английский
Процитировано
1
International Reviews of Immunology, Год журнала: 2022, Номер 42(4), С. 287 - 303
Опубликована: Июль 6, 2022
Metabolic reprogramming is a hallmark of solid cancers. Macrophages as major constituents immune system take important roles in regulation tumorigenesis. Pro-tumor M2 macrophages preferentially use oxidative phosphorylation (OXPHOS) to meet their metabolic demands, while anti-tumor M1 glycolysis dominant source. Dysregulation systems driving force skewing from toward phenotypical state. Hyperactive macrophages, for instance, release products that are contributed macrophage polarization. Thus, remodeling through reinstating normalization can be an effective tool cancer therapy. The key focus this review over and factors influencing acquisition cancer, well discussing bout strategies adjust metabolism reeducation M1-like phenotype.
Язык: Английский
Процитировано
17
Heliyon, Год журнала: 2023, Номер 9(12), С. e23171 - e23171
Опубликована: Дек. 1, 2023
Tumor-mediated bypass of immune checkpoint inhibitor (ICI) therapy with anti-programmed death-1 (PD-1), death-ligand 1 (PD-L1, also called B7-H1 or CD274) anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is a challenge current years in the area cancer immunotherapy. Alternative checkpoints (AICs) are molecules beyond common PD-1, PD-L1 CTLA-4, and upregulated patients who show low/no ICI responses. These members B7 family including B7-H2 (ICOS-L), B7-H3 (CD276), B7-H4 (B7x), V-domain immunoglobulin suppressor cell activation (VISTA), B7-H6, HHLA2 (B7-H5/B7-H7) catabolic enzymes like indoleamine 2,3-dioxygenase (IDO1), others that contributed to regulation tumor microenvironment (TIME). There strong evidence supporting implication AICs stemness expanding population stem cells (CSCs). CSCs display immunoregulatory capacity represent multiple either on their surface inside. Besides, they active promoters resistance ICIs. The aim this review investigate interrelations between differentiation profile cancer. key message paper targeted can be selected based impact along effect cells. Studies published so far mainly focused as target for anti-checkpoints. Ex vivo engineering extracellular vesicles (EVs) equipped CSC-targeted anti-checkpoint antibodies without doubt therapeutic under consideration future research.
Язык: Английский
Процитировано
11
Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)
Опубликована: Май 14, 2025
Язык: Английский
Процитировано
0
Medical Oncology, Год журнала: 2022, Номер 40(1)
Опубликована: Дек. 2, 2022
Язык: Английский
Процитировано
14
Discover Oncology, Год журнала: 2024, Номер 15(1)
Опубликована: Сен. 2, 2024
Cluster of differentiation 24 (CD24) is a highly glycosylated glycosylphosphatidylinositol (GPI)-anchored surface protein, expressed in various tumor cells, as "don't eat me" signaling molecule immune. This study aimed to investigate the potential features CD24 pan-cancer. The correlations between 22 immune cells and expression were using TIMER analysis. R package "ESTIMATE" was used predict proportion stromal Spearman's correlation analysis performed evaluate relationships checkpoints, chemokines, mismatch repair, mutation burden microsatellite instability, qPCR western blot conducted assess levels liver hepatocellular carcinoma (LIHC). In addition, loss function for biological evaluation LIHC. positively correlated with myeloid including neutrophils myeloid-derived suppressor tumors, such BLCA, HNSC-HPV, HNSC, KICH, KIRC, KIRP, TGCT, THCA, THYM, UCEC. contrast, anti-tumor NK NKT showed negative association BRCA-Her2, ESCA, THYM. top three tumors highest ImmuneScore SKCM. Functional enrichment revealed negatively associated immune-related pathways. Immune checkpoints chemokines also exhibited inverse CESC, CHOL, COAD, READ, THCA. Additionally, overexpressed most high BRCA, LIHC, CESC correlating poor prognosis. TIDE database indicated expression, particularly melanoma, less responsive PD1/PD-L1 immunotherapy. Finally, knockdown resulted impaired proliferation cell cycle progression participates regulation infiltration, influences patient prognosis serves marker.
Язык: Английский
Процитировано
2
International Journal of Nanomedicine, Год журнала: 2023, Номер Volume 18, С. 35 - 48
Опубликована: Янв. 1, 2023
Abstract: Cancer is a broad term for group of diseases involving uncontrolled cell growth and proliferation. There no cure cancer despite recent significant improvements in screening, treatment, prevention approaches. Among the available treatments, immunotherapy has been successful targeting killing cells by stimulating or enhancing body's immune system. Antibody-based immunotherapeutic agents that block checkpoint proteins expressed have shown promising results. The rapid development nanotechnology contributed to improving effectiveness reducing adverse effects these anti-cancer agents. Recently, engineered nanomaterials focus many state-of-The-art approaches toward effective treatment. In this review, contribution various such as polymeric nanoparticles, dendrimers, microspheres, carbon efficiency discussed well nanostructures applied combination immunotherapy. Keywords: nanotechnology, therapy, nanomaterials, nanotoxicity, synergistic therapy
Язык: Английский
Процитировано
5